Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:ARDX

Ardelyx Q3 2026 Earnings Date & Estimates

Ardelyx logo
$3.08 -0.12 (-3.75%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.11 +0.03 (+0.94%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ardelyx is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ardelyx in Q3 2026

Ardelyx is expected to post earnings of -$0.0148 per share on revenue of $128.66 million. In the same quarter a year earlier Ardelyx reported -$0.0040 per share on revenue of $110.33 million. Ardelyx last reported on August 6, 2026, posting -$0.07 per share and missing the -$0.05 consensus estimate. Ardelyx has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0148
Expected Revenue
$128.66 million
Prior-Year EPS
-$0.0040
Prior-Year Revenue
$110.33 million
Expected Revenue Growth
+16.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.07 (Missed by -$0.02)
Last Quarter Revenue
$120.88 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Ardelyx Q3 2026 Earnings FAQ

Ardelyx (NASDAQ:ARDX) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Ardelyx's Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ardelyx to post earnings of -$0.0148 per share for Q3 2026.

The consensus revenue estimate for Ardelyx is $128.66 million for Q3 2026.

Ardelyx Earnings Headlines

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
October 23 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/23/3387604/0/en/ardelyx-presents-real-world-data-at-asn-kidney-week-2026-showing-serum-phosphate-reductions-following-xphozah-tenapanor-initiation-with-or-without-phosphate-binders.html
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
October 23 at 11:15 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/23/3387489/0/en/ardx-investors-have-opportunity-to-lead-ardelyx-inc-securities-fraud-lawsuit-with-sbs-law.html
CrashGPT coming on Dec. 18 …
Sam Altman is expected to reveal a confidential OpenAI document around 4 p.m. on Dec. 18, just weeks before a potential IPO. The disclosure could trigger a 40 trillion dollar wealth shift. Altman himself has warned that someone is going to lose a phenomenal amount of money while others gain just as much.tc pixel
October 24 at 1:00 AM  |  Weiss Ratings (Ad)
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
October 22 at 11:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386651/9788/en/bronstein-gewirtz-grossman-llc-urges-ardelyx-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallSt
October 22 at 10:11 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ardx-shareholder-alert-november-16-2026-lead-plaintiff-deadline-in-ardelyx-inc-securities-class-action---contact-suewallst-302916575.html
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
October 22 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-ardelyx-inc-of-class-action-lawsuit-and-upcoming-deadlines--ardx-302916521.html
See More Ardelyx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email.

About Ardelyx

Ardelyx (NASDAQ:ARDX) is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders. Both products are available in the United States.

Founded in 2007, Ardelyx is headquartered in Waltham, Massachusetts. In addition to its commercial products, the company continues to advance an investigational pipeline focused on gastrointestinal and cardiorenal disorders. Ardelyx is led by President and Chief Executive Officer Mike Raab.

View Ardelyx Profile
Earnings Tools